A rare but serious complication of ticagrelor therapy: a case report.
Manfredi AriotiGiovanni SirianniMaria Luisa LaudisaNicoletta Bianca De CesarePublished in: European heart journal. Case reports (2020)
Despite ventricular pauses have been reported in dedicated analyses of Phase III trials, no apparent clinical consequences were documented. However, several reports have shown that significant brady-arrhythmic events might be linked to ticagrelor administration presenting both as sino-atrial and atrio-ventricular conduction disturbances. We report a case of asystole occurring 36 h after the administration of a loading dose.
Keyphrases
- phase iii
- catheter ablation
- acute coronary syndrome
- percutaneous coronary intervention
- open label
- heart failure
- left ventricular
- atrial fibrillation
- st elevation myocardial infarction
- antiplatelet therapy
- st segment elevation myocardial infarction
- clinical trial
- left atrial
- double blind
- phase ii
- placebo controlled
- coronary artery disease
- case report
- stem cells
- adverse drug
- computed tomography
- mitral valve
- bone marrow
- study protocol